Streetbeat News

Earnings

CAE

The article discusses Wall Street's estimates for CAE's financial performance in Q2, focusing on key metrics to understand the company's potential performance for the quarter ending September 2024.

Portfolio Pulse from

November 07, 2024 | 3:30 pm

AZN

The article discusses Astrazeneca's (AZN) Q3 outlook, focusing on Wall Street's estimates for key metrics to assess the company's potential performance for the quarter ending September 2024.

Portfolio Pulse from

November 07, 2024 | 3:30 pm

PJT

PJT Partners Inc. (PJT) has reached a 52-week high, prompting questions about its potential for further gains. The article examines the company's fundamentals to assess future prospects.

Portfolio Pulse from

November 07, 2024 | 3:30 pm

APD

Air Products reported Q4 earnings that exceeded estimates, but revenues fell short. The flat sales were due to a 1% increase in volumes and pricing, offset by a 2% decrease in energy cost pass-through.

Portfolio Pulse from

November 07, 2024 | 3:30 pm

DOX

The article discusses the upcoming Q4 earnings report for Amdocs (DOX), focusing on key metrics beyond traditional revenue and EPS estimates to evaluate the company's performance for the quarter ended September 2024.

Portfolio Pulse from

November 07, 2024 | 3:30 pm

ATSG

The article evaluates the expected performance of Air Transport Services (ATSG) for Q3 2024, focusing on key metrics beyond traditional Wall Street estimates.

Portfolio Pulse from

November 07, 2024 | 3:30 pm

FOUR

Shift4 Payments (FOUR) is set to release its Q3 earnings, with a focus on key metrics beyond top-and-bottom-line estimates to assess its performance for the quarter ended September 2024.

Portfolio Pulse from

November 07, 2024 | 3:30 pm

HD

The article evaluates Home Depot's (HD) expected performance for Q3 2024, focusing on key metrics beyond traditional Wall Street estimates to provide deeper insights into the company's earnings.

Portfolio Pulse from

November 07, 2024 | 3:30 pm

SAVA

Cassava Sciences, Inc. (SAVA) held its Q3 2024 earnings call, discussing financial results and company updates.

Portfolio Pulse from

November 07, 2024 | 3:30 pm

SRPT

Sarepta Therapeutics reported strong Q3 earnings and sales, but announced the discontinuation of its PPMO-based DMD program after a risk-benefit analysis.

Portfolio Pulse from

November 07, 2024 | 3:30 pm